Newron Points ‘Future Value-Driver’ Evenamide At Drug-Resistant Schizophrenia
Following Phase II Promise
The Italian firm’s VGSC-blocker has demonstrated long-term symptom improvement in a mid-stage trial in drug-resistant schizophrenia, expediting Phase III development plans that could help address a high unmet need.
